Can-c™ Eye Drops May Help Senile Cataracts Become A Health Condition Of The Past

Senile cataracts are a visual impairment brought about by the gradual and progressive thickening of the ocular lens which leads to the loss of lens’ transparency, slowly diminishing a person’s ability to see clearly. The term ‘senile’ is often used simply because this disease primarily affects aging people usually in the age group, 50 and above. Cataract is characterized by the opacification of the ocular lens which can be seen as a cloudy appearance of the lens, usually yellowish or brownish in color. A person affected with cataracts may also have noticeable brownish tinted vision. Other symptoms would include blurriness of vision glare sensitivity, problems with night vision, double vision or multiple images in one eye, accompanied by the need for frequent changes in eyeglass or contact lens prescription strength.

In the U.S. alone, at least 300, 000 – 400, 000 new cataract cases occur annually. This disease is a common cause of blindness in elderly people when not treated. A comprehensive eye examination which includes visual acuity test (vision exam at various distances), dilated eye exam and tonometry (measurement of the pressure inside the eye) is needed to detect cataracts. The most common treatment is surgery in which the cloudy lens is removed and replaced with an artificial lens called intraocular lens (IOL). Intraocular lens is a clear plastic lens which can focus light clearly on to the retina once again. Cataract surgery is not totally without risk however, as opacification of the posterior lens capsule occurs in 30-50% of patients within 2 years of surgical cataract removal and require secondary laser treatment; further 0.8% experience retinal detachments, approximately 1% are re-hospitalized for corneal problems, and about 0.1% develop endophthalmitis.

The use of Can-C™ eye drops containing this unique purity of, N-Acetylcarnosine, in safely managing cataract is a major advancement in the medical world. For the first time, cataract can now be effectively reversed without having to resort to the risks of eye surgery.

N-Acetylcarnosine or NAC is a molecule that’s found naturally in the human body. Its parent compound, carnosine, can be naturally found in foods and in human cells. Carnosine is found primarily in the tissues of the heart, skeletal muscles, the brain and in and throughout eye. This natural di-peptide (two amino acids linked together) acts as an antioxidant and as an inhibitor of the body’s glycation process which is a degenerative chemical process that contributes to aging throughout the body. As we age our natural carnosine levels decreases which leave the eye vulnerable to ocular disease such as cataracts. Unfortunately oral consumption of carnosine rich foods or supplements is not bioavailable to the eyes and so restoring these levels systemically is not reliable.

In Russia, where carnosine deficiency in the eyes was first discovered as a fundamental precursor to ocular disease, the use of topical N-acetylcarnosine; to effectively address cataracts in the form of Can-C™ eye drops was established.
In 2001, Can-C™ eye drops were trialed in a; double blind, placebo based, human study for a period of 6 months. The impressive results showed that 90% had visual acuity improvement, 88.9% had glare sensitivity improvement and 41.5 % had an improvement in the transmissivity of the lens.

With the market release of the product by Innovative Visions Product (IVP), 7 years ago, thousands of people affected with senile cataracts have reported vast improvement in their vision after applying Can-C™ cataract eye drops for a period of 6-12 months.

Dr. Mark Babizhayev, MA, PhD, the principal researcher in the development of Can-C™ eye drops cautions consumers before purchasing any eye drops containing N-acetylcarnosine to look for the words, “Approved by Innovative Vision Products” on the label. This is your assurance that the product contains the proprietary purity of raw material and is the formula that was proven to have long-term efficacy in clinical trials.